May 11, 2026 8:19 am EDT VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update
May 6, 2026 8:17 am EDT VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
Apr 29, 2026 8:17 am EDT Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing
Mar 31, 2026 4:05 pm EDT VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
Mar 31, 2026 8:16 am EDT VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
Mar 30, 2026 8:13 am EDT Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
Mar 26, 2026 8:17 am EDT Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
Mar 25, 2026 4:12 pm EDT VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
